Cargando…
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
BACKGROUND: Although immune checkpoint inhibitors (ICIs) against programmed cell death protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients with non‐small cell lung carcinoma (NSCLC), the potential association between Kirsten rat sarcoma viral oncogene homolog (K...
Autores principales: | Liu, Chengming, Zheng, Sufei, Wang, Zhanyu, Wang, Sihui, Wang, Xinfeng, Yang, Lu, Xu, Haiyan, Cao, Zheng, Feng, Xiaoli, Xue, Qi, Wang, Yan, Sun, Nan, He, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456691/ https://www.ncbi.nlm.nih.gov/pubmed/35811500 http://dx.doi.org/10.1002/cac2.12327 |
Ejemplares similares
-
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020) -
Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021) -
S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
por: Liu, Chengming, et al.
Publicado: (2022) -
Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022) -
Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)